These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30790732)

  • 1. Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma.
    Henker C; Kriesen T; Schneider B; Glass Ä; Scherer M; Langner S; Erbersdobler A; Piek J
    World Neurosurg; 2019 May; 125():e1093-e1103. PubMed ID: 30790732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
    Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
    Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 Proliferative Activity in the Tumor Margins as a Robust Prognosis Factor in Glioblastoma Patients.
    Tejada S; Becerra-Castro MV; Nuñez-Cordoba J; Díez-Valle R
    J Neurol Surg A Cent Eur Neurosurg; 2021 Jan; 82(1):53-58. PubMed ID: 33260244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas.
    Eneström S; Vavruch L; Frånlund B; Nordenskjöld B
    Neurochirurgie; 1998 Mar; 44(1):25-30. PubMed ID: 9757314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
    Fudaba H; Momii Y; Matsuta H; Onishi K; Kawasaki Y; Sugita K; Shimomura T; Fujiki M
    World Neurosurg; 2021 May; 149():e469-e480. PubMed ID: 33567368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different assessments of immunohistochemically stained Ki-67 and hTERT in glioblastoma multiforme yield variable results: a study with reference to survival prognosis.
    Persson A; Englund E
    Clin Neuropathol; 2008; 27(4):224-33. PubMed ID: 18666438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival.
    Henker C; Kriesen T; Glass Ä; Schneider B; Piek J
    J Neurooncol; 2017 Nov; 135(2):391-402. PubMed ID: 28755324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma.
    Petrik V; Saadoun S; Loosemore A; Hobbs J; Opstad KS; Sheldon J; Tarelli E; Howe FA; Bell BA; Papadopoulos MC
    Clin Chem; 2008 Apr; 54(4):713-22. PubMed ID: 18281421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 labeling index in glioblastoma; does it really matter?
    Alkhaibary A; Alassiri AH; AlSufiani F; Alharbi MA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):82-88. PubMed ID: 30552865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractional Anisotropy Correlates with Overall Survival in Glioblastoma.
    Huber T; Bette S; Wiestler B; Gempt J; Gerhardt J; Delbridge C; Barz M; Meyer B; Zimmer C; Kirschke JS
    World Neurosurg; 2016 Nov; 95():525-534.e1. PubMed ID: 27565465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.
    Seidel C; Dörner N; Osswald M; Wick A; Platten M; Bendszus M; Wick W
    BMC Cancer; 2011 Apr; 11():127. PubMed ID: 21481277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
    Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
    Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric assessment of glioblastoma and its predictive value for survival.
    Henker C; Hiepel MC; Kriesen T; Scherer M; Glass Ä; Herold-Mende C; Bendszus M; Langner S; Weber MA; Schneider B; Unterberg A; Piek J
    Acta Neurochir (Wien); 2019 Aug; 161(8):1723-1732. PubMed ID: 31254065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma.
    Pérez-Beteta J; Molina-García D; Martínez-González A; Henares-Molina A; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; Martino J; Velásquez C; Meléndez-Asensio B; de Lope ÁR; Moreno R; Barcia JA; Asenjo B; Benavides M; Herruzo I; Lara PC; Cabrera R; Albillo D; Navarro M; Pérez-Romasanta LA; Revert A; Arana E; Pérez-García VM
    Eur Radiol; 2019 Apr; 29(4):1968-1977. PubMed ID: 30324390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
    Chiba Y; Hashimoto N; Tsuboi A; Rabo C; Oka Y; Kinoshita M; Kagawa N; Oji Y; Sugiyama H; Yoshimine T
    Brain Tumor Pathol; 2010 Apr; 27(1):29-34. PubMed ID: 20425045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.